Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 16th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 16th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

February 14th 2014

Three Ways to Make Cancer Care More Affordable

The malady of rising medical costs is acute, especially in the field of oncology. As populations age, new cancer cases are expected to reach 21.4 million in 2030, while treatment costs are projected to increase 40 percent by 2020.

February 14th 2014

Are Oncology Clinical Pathways Coming to Medicare?

Oncology clinical pathways have helped health plans deliver quality care while keeping an eye on costs. The lack of standardization in pathways can be cumbersome on a busy oncology practice. If Medicare adopts a pathways model, it could offer a framework for broader use.

February 13th 2014

FDA Grants Accelerated Approval for Ibrutinib for CLL

Surabhi Dangi-Garimella, PhD

The US Food and Drug Administration (FDA) on Wednesday granted accelerated approval for the expanded use of ibrutinib, marketed as Imbruvica, for chronic lymphocytic leukemia (CLL) patients who have previously received at least one therapy. The therapy is notable for its relative lack of toxic effects.

February 12th 2014

Value of the Mammogram Questioned

Katie Sullivan

The value of the mammogram is being questioned after 1 study found that the mortality rates resulting from breast cancer were the same in women who got screened and those who did not.

February 7th 2014

Expanded DNA Testing Might Allow Personalized Breast Cancer Treatment

Testing the entire genetic makeup -- or all the DNA -- of tumor cells from women with advanced breast cancer may help identify patients who could be helped by specific treatments, according to new research.

February 6th 2014

CVS Wins Plaudits for Vowing to Stop Tobacco Sales

Drugstore giant CVS Caremark's decision to stop selling tobacco products at its stores is being hailed as a victory among public health advocates, a move they predict will force CVS competitors to follow suit as they look to play a growing part in the delivery of the country's healthcare.

February 6th 2014

Co-payment Coupons and Patient Assistance Programs: Just 1 Piece of the Specialty Drug Management Puzzle

Pat Gleason, PharmD, FCCP, BCPS, director of health outcomes, Prime Therapeutics, and Shelley Sanchez, senior director of specialty product development, Prime Therapeutics, presented on 1 approach to managing the specialty drug benefit, which includes optimizing the use of PhARMA manufacturer coupons and patient assistance programs (PAPs).

February 6th 2014

Implications of the Health Insurance Exchange Marketplace and State Law Trends on Commercial Pharmacy

Presenters in this talk focused on how the creation of health insurance exchanges (HIEs) and other federal and state regulations will impact the provision and administration of pharmacy benefits.

February 6th 2014

Healthcare Industry Transformation to Meet Employer Demand for Managing Specialty Pharmacy Costs

According to Howard K. Crowley, head of pharmacy strategic initiatives, Aetna Pharmacy Management, a Towers Watson/ National Business Group on Health survey found that 29% of employers rank the rising costs of specialty drugs as a top challenge to keeping health benefit coverage affordable.

February 5th 2014

Pharmacy Benefit Management Institute Conference Highlights - Part 2

Katie Sullivan

This week AJMC is covering session highlights from the PBMI Annual Drug Benefit conference.

January 30th 2014

Chris Belmont Discusses How Hospitals Manage Health Information

Chris Belmont, vice president and chief information officer, MD Anderson Cancer Center, says the right timing and the right context are essential to effective health data management.

January 28th 2014

Karen Lewis, MS, MM, CGC, Discusses Oncology and Genetic Testing

Karen Lewis, MS, MM, CGC, says the goals of Healthy People 2020 are developed by looking at a variety of key areas in healthcare, and then choosing the most actionable items to improve the overall health of the general population.

January 27th 2014

Doctors, Older Patients Rethink Cancer Treatments

Experts in treating older cancer patients say it's important to think of each patient individually, not to assume that because someone has reached a certain age that he or she isn't going to be able to withstand surgeries, radiation or chemotherapy.

January 23rd 2014

COA and ASCO Issue Joint Statement on Oncology Payment Reform

COA and ASCO are issuing a joint statement on payment reform in cancer care. The goal is to improve the lives of individuals with cancer, in part by developing and supporting payment systems based on evidence-based medicine and measures of quality and value in cancer care.

January 22nd 2014

Drugmakers See Innovation Justifying Further Price Rises

As U.S. consumers are asked to shoulder more prescription drug costs, drugmakers say prices for brand-name medicines will keep rising, mainly because use of their products reduces other healthcare costs.

January 21st 2014

Amy Berman, BS, RN, Discusses Patient-Centered Oncology Care

Amy Berman, BS, RN, says that all too often, people end up in the hospital because they don't know where else to go for treatment.

January 17th 2014

Custom-Fit Treatments for Prostate Cancer

In a bid to improve treatment for men with high-risk prostate cancer, some researchers want to take a page from the playbook for breast cancer.

January 16th 2014

Scott Ramsey, MD, PhD, on Health Economics and Outcomes Research in Oncology

Scott Ramsey, MD, PhD, Fred Hutchinson Cancer Research Center, says that right now, only a small portion of health economics and outcomes research (HEOR) fits into the oncology model.

January 13th 2014

Comorbidities and Cardiovascular Disease Risk in Older Breast Cancer Survivors

Reina Haque, PhD, MPH Marianne Prout, MD Ann M. Geiger, PhD Aruna Kamineni, PhD Soe Soe Thwin, PhD Chantal Avila, MA Rebecca A. Silliman, MD, PhD Virginia Quinn, PhD Marianne Ulcickas Yood, DSc

Effective management of the comorbidities of diabetes and hypertension may increase survival in older breast cancer survivors.

January 10th 2014

For High-Risk Women, Some Breast Cancer Drugs To Be Free

Starting next September, women at increased risk for breast cancer will be able to get some drugs shown to help prevent the disease without a co-pay, the Obama administration said Thursday.

January 2nd 2014

Segment 8 - Treatment's Financial Constraints

The panelists discuss clinicians and their perspectives on financial constraints in treatment of NSCLC.

January 2nd 2014

Segment 7 - Cost Considerations

Dr Peskin begins by stating, costs are exceedingly consequential. Cancer care and treatment is occupying, and with demographics being what they are, increasingly larger relative total cost of care across the US, including various national organizations.

January 2nd 2014

Segment 5 - Value-based Decisions in NSCLC

Dr Peskin discusses programs such as Choosing Wisely and how providers must be mindful of high value, cost-conscious, cost-aware care.

December 31st 2013

Healthcare Headlines in 2013

Katie Sullivan

A look back at some of the InFocus blog highlights of 2013.

December 30th 2013

Segment 4 - Screening

Panelists discuss screening recommendations and guidelines, including considerations for screening those patients with a smoking history.

December 30th 2013

Segment 3 - Treatment Considerations

The panelists weigh in on the appropriate standards for treating patients with NSCLC.

December 30th 2013

Segment 2 - Histology, Targeted Therapy and Surgery

Dr Langer suggests that historically, there's been a monolithic approach to treating NSCLC.

December 30th 2013

Segment 1 - Introduction to NSCLC

Moderator Michael Chernew, MD, introduces panelists as they discuss the treatment overview of non-small cell lung cancer (NSCLC).

December 30th 2013

For Cancer Survivors, 2014 Will Be the Year to Plan

The coming year will be one for those who have beaten cancer to develop survivorship plans, with the Commission on Cancer to require planning by treatment centers starting in 2015.

December 28th 2013

Discussion 8: Redefining the Role of Industry in Contemporary Healthcare

Cliff Goodman, PhD John L. Fox, MD, MHA Bo Gamble

The final panel of the conference analyzes the role of the industry in healthcare, including panelists' observations on topics such as innovation. Mr Gamble, for instance, offers his insights as to how groups like the Community Oncology Alliance are working with the industry to drive the message about the quality and the value component throughout all the stakeholders. Dr Fox provides perspective on how payers can offer valuable partnerships throughout the industry, including those with pharmaceutical companies.

...

168 169 170 171 172 173 174 175 176

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions